Responses
Ovarian Cancer
A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Trial
Compose a Response to This Article
Other responses
No responses have been published for this article.